Young blood not required
Category: biotech/medical – Page 2,250
New technological devices are prioritizing non-invasive tracking of vital signs, not only for fitness monitoring, but also for the prevention of common health problems such as heart failure, hypertension and stress-related complications, among others. Wearables based on optical detection mechanisms are proving an invaluable approach for reporting on our bodies inner workings and have experienced a large penetration into the consumer market in recent years. Current wearable technologies, based on non-flexible components, do not deliver the desired accuracy and can only monitor a limited number of vital signs. To tackle this problem, conformable non-invasive optical-based sensors that can measure a broader set of vital signs are at the top of the end-users’ wish list.
In a recent study published in Science Advances, ICFO researchers have demonstrated a new class of flexible and transparent wearable devices that are conformable to the skin and can provide continuous and accurate measurements of multiple human vital signs. These devices can measure heart rate, respiration rate and blood pulse oxygenation, as well as exposure to UV radiation from the sun. While the device measures the different parameters, the read-out is visualized and stored on a mobile phone interface connected to the wearable via Bluetooth. In addition, the device can operate battery-free since it is charged wirelessly through the phone.
“It was very important for us to demonstrate the wide range of potential applications for our advanced light sensing technology through the creation of various prototypes, including the flexible and transparent bracelet, the health patch integrated on a mobile phone and the UV monitoring patch for sun exposure. They have shown to be versatile and efficient due to these unique features,” reports Dr. Emre Ozan Polat, first author of this publication.
Recent genome-wide association studies have catapulted the search for genes underlying human intelligence into a new era. Genome-wide polygenic scores promise to transform research on individual differences in intelligence, but not without societal and ethical implications, as the authors discuss in this Review.
Cryotechnology has been used in treating lung cancer for many years, now it is emerging to have a new indication in diagnosing lung diseases. Cryoprobe transbronchial lung biopsy has been introduced into clinical practice as a new technique, providing a larger biopsy specimen, potentially improving the diagnostic yield of transbronchial biopsies in parenchymal lung diseases. Although recent small pilot studies suggest that cryotransbronchial lung biopsies are comparable to conventional transbronchial biopsies in terms of diagnostic yield and safety profile in lung transplant patients, cryoprobe transbronchial lung biopsy is still being evaluated and its role in clinical practice is not well defined. Cryotherapy has been proven as a safe and effective method to debulk endobronchial lesions, providing palliation for advanced central obstructive tumors. Its use and efficacy is also studied in direct cryosurgery and percutaneous application in lung cancer. Cryoprobes can also be used to extract foreign bodies from the airways by causing cryoadhesion. We aim to summarize the therapeutic and diagnostic application of cryotechnology in pulmonary diseases.
Ischemic stroke is a condition in which parts of the brain lose their blood supply, causing nerve damage. Once brain tissue suffers irreparable harm, the patient will experience irreversible disability or death, depending on the extent of neuronal loss. However, glial cells surrounding the neurons are activated by the injury and multiply. Now, scientists have found out how to insert genes into glial cells to convert them into neurons, thus filling in for some of the lost functioning cells to improve motor functions.
There are about 86 billion neurons in the brain, but billions of them can be lost with one moderate-sized stroke. About 800,000 new strokes occur each year in the US alone. The need is to regenerate new brain cells to replace the ones that die, at least partially. This is the only known way to restore motor functions that have been impaired or destroyed by a stroke or other brain injury.
Heartburn drug Zantac has been found to be contaminated with low levels of a cancer-linked chemical. This is the same contaminant that lead to multiple recalls of blood pressure drugs.
Mei Mei Hu vowed to never work with her mother, Chang Yi, but she knew this was bigger than the both of them.
Having a loved one not recognize you, or forget a shared experience can be heartbreaking but that’s what Alzheimer’s does to you. We are, ultimately, nothing but the sum of our memories and experiences, so to lose the ability to remember is to lose one’s identity. Alzheimer’s is currently the sixth-largest cause for death in the United States with over 5.8 million Americans diagnosed with the memory loss disease. After 200 unsuccessful attempts worldwide to find a drug that treats Alzheimer’s, a mother-daughter duo is now close to finding a vaccine, according to Wired.
Today, we’re offering another talk from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.
In her talk, Morgan Levine of the Yale School of Medicine discussed epigenetic biomarkers in detail, discussing the ways in which co-methylation networks provide insight into senescent cells and other facets of biological age.
I’m excited to share my new article for The New York Times on the brave new world of #cyborg ability and coming #transhumanism sports:
I wonder whether the sporting industry might create some new competitions where — just like technology — performance-enhancing drugs are encouraged. Innovations like the new oxygen-infused injection, which might one day allow humans to hold their breath for 15 to 30 minutes, could allow competitive free divers to reach new depths, showing just how far the human body can go.
Critics will complain that the human body was not designed to compete using enhancements and that it violates the code given to us by the ancient Greeks and their first Olympics Games, where “arête,” or excellence and moral virtue, was cherished. As a longtime competitive athlete, I appreciate the sportsmanship angle; but I also think that in the 21st century we can develop both the drugs and the technology to see humans compete in new sporting events that are even more exciting than their predecessors.
It’s hard to imagine the public wouldn’t want to see swimmers with fingers surgically webbed together to act like paddles, or weight lifters using short-lasting adrenaline shots, or 150-mile-per-hour baseball pitches thrown from bionic limbs.
Drugs and performance-enhancing technology would not have to challenge any existing sporting competitions and their cultures. It would simply be a new category of sports with different athletes. And like the Cybathlon, these types of competition do more than just entertain — they lead the way forward for the medical and transhumanist industries seeking to improve the human being. Competitions would be pilgrimages for medical professionals and entrepreneurs looking to buy and possibly mass produce the latest unique technologies.
We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.
Today, we’re releasing a talk from Dr. Doug Ethell, who announced his company’s efforts to combat Alzheimer’s disease, describing where and how this neurodegenerative disease starts and discussing his company’s work on developing therapies for the cribiform plate, which naturally clears amyloid-forming proteins from the brain before they aggregate.